Enhancing Alzheimer's Care: The Collaboration Between InRAD and icometrix

Discover EAN 2025 in Helsinki

Attending EAN 2025 in Helsinki and want to learn more about this collaboration or the icobrain portfolio? Reach out to info@icometrix.com to schedule a meeting - or join us at the Philips & icometrix Evening Event featuring a keynote by Prof. Tiago Gil Oliveira on “New Paradigms in Alzheimer’s Disease in Europe”. Register here.

Strategic Collaboration for Alzheimer's Disease

The International Registry for Alzheimer's Disease and Other Dementias (InRAD) and icometrix have entered into a strategic collaboration. Their goal is to improve the standardisation of real-world evidence generation and care for people with Alzheimer’s disease (AD) who receive approved disease-modifying therapies (DMTs).

icometrix has developed the first FDA-cleared and CE-marked AI solutions (icobrain). These solutions quantify brain MRI scans to support diagnosis and safety monitoring for people with AD on DMTs. Standardisation of MRI workflows and reporting is crucial for monitoring new treatments for Alzheimer’s disease. This collaboration aligns closely with InRAD’s mission to enhance the standardised collection of real-world data. It aims to provide much-needed evidence in Alzheimer’s disease to address important questions.

The long-term objectives of the partnership include enabling a frictionless integration of pseudonymised imaging outcomes into the InRAD registry for those using the icometrix pipeline.

The Impact of Alzheimer's Disease in Europe

Mild cognitive impairment (MCI) due to AD and AD dementia currently affects around 15 million and 7 million people in Europe, respectively (Gustavsson et al. 2023). In April 2025, the European Commission granted marketing authorisation in the European Union to the first therapy targeting an underlying cause of AD. Early diagnosis and treatment safety monitoring are fundamental to this and future therapies on the horizon. MRI scan quantification plays a key role in this process.

Collecting imaging data as part of a minimum real-world dataset is essential. This step is crucial for realising insights that will support clinical practice and patient management for years to come.

The Importance of Real-World Data

“Collecting real-world AD data at scale will be essential for generating insights, standardising care pathways, informing future research, and market access of new treatments,” says Prof. Robert Perneczky, co-founder and Chairman of the InRAD Board and Professor of Translational Dementia Research at Ludwig-Maximilians University in Munich, Germany. “The goal of InRAD is therefore to collect meaningful data with a sustainable platform through collaborative science.”

“Collaborations with solutions partners such as icometrix is an important next step for InRAD and people with AD,” says Jean Georges, InRAD Board member and Executive Director of Alzheimer Europe. “It is only by unifying the field and working together that we can prevent fragmentation in data collection and analysis,” he continues.

Prof. Philip Scheltens, InRAD Board member and head of the Dementia Fund at EQT Life Sciences, adds: “Today it is of utmost importance to support standardisation of workflows and enable outcomes from AI-based MRI quantification to be collected. Hence, we are very happy to start this partnership with icometrix.”

Raising Awareness and Streamlining Access

InRAD and icometrix will collaborate closely to create awareness of the importance of standardisation of MRI approaches, ARIA monitoring, and real-world data collection. Furthermore, this partnership will streamline the implementation and access to icometrix’s AI solutions as well as the InRAD registry in centres adopting both approaches.

“Because of the ageing population, we are tackling one of the largest healthcare challenges of our time and the future. And that is why collaborative projects such as the one with InRAD are so important,” says Wim Van Hecke, founder and CEO of icometrix. “Real-world data collection at scale is key to impacting our understanding of complex neurological conditions such as Alzheimer’s disease, and InRAD is leading these efforts. That is why this collaboration is so important and timely,” he concludes.

About InRAD

InRAD is a free registry that assists with the collection, combination, and comparison of real-world data. The registry is coordinated by the independent International Registry for Alzheimer’s Disease and Other Dementias Foundation, a health-related not-for-profit entity incorporated in the Netherlands.

The registry platform will launch in 2025. It will provide a secure, regionally compliant, Azure cloud-based way to share and store data for Alzheimer’s disease research. For more information, visit https://www.inradnetwork.org/.

About icometrix

icometrix is a global leader in AI-driven software for brain imaging. They transform MRI and CT scans into actionable data for neurological conditions such as Alzheimer’s, multiple sclerosis, and Parkinson’s disease. Used in hospitals worldwide, icobrain technology is setting new standards in precision brain health. It supports radiologists and neurologists with FDA-cleared solutions that impact workflows, clinical decision-making, and patient care.

With a commitment to advancing safe, effective treatments, icometrix partners with scientific societies, patient organizations, academic and private practice medical centers, pharmaceutical and health tech companies to bring innovative solutions to those who need them most.

For more information on icobrain and icobrain aria, visit icometrix.com or contact info@icometrix.com.

*icobrain aria is 510(k) cleared. CE marked as part of icobrain mr. Not available in all markets.